{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:23:50Z","timestamp":1790508230436,"version":"4.1.0"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>\n                    Prostate cancer is a malignant tumor posing significant threats to the health of men worldwide. In advanced stages, it frequently progresses to castration-resistant prostate cancer, which is characterized by complex mechanisms and poor prognosis. In such cases, conventional treatments have limited effectiveness. However, the emergence of radionuclide therapy has provided new hope. Lutetium-177-labeled prostate-specific membrane antigen (\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA), currently the most promising radioligand in clinical research, received approval from the U.S. Food and Drug Administration (FDA) in 2022. This review comprehensively summarizes recent advancements, efficacy assessments, and safety evaluations of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA therapy. Additionally, we analyze its current limitations and suggest future research directions for PSMA-targeted radioligand therapy (RLT). Undoubtedly,\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617 is transforming metastatic castration-resistant prostate cancer (mCRPC) treatment. However, challenges remain regarding its potential standardization for use in non-mCRPC cases, the optimal treatment sequence, standardized imaging\/molecular biomarkers, and toxicity management, all of which require further prospective validation.\n                  <\/jats:p>","DOI":"10.4103\/aja2025103","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:01:02Z","timestamp":1770958862000},"page":"467-477","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["177Lu-PSMA for prostate cancer: progress, challenges and future perspectives"],"prefix":"10.4103","volume":"28","author":[{"given":"Zhen","family":"Xi","sequence":"first","affiliation":[{"name":"Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Yu","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hui","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao-Zhen","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"R1-20260905","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260905","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","article-title":"Epidemiology and genomics of prostate cancer in Asian men","volume":"18","author":"Zhu","year":"2021","journal-title":"Nat Rev Urol"},{"key":"R3-20260905","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s11912-024-01614-6","article-title":"Prostate cancer, pathophysiology and recent developments in management: a narrative review","volume":"26","author":"Almeeri","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"R4-20260905","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R5-20260905","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.3390\/ijms22073753","article-title":"Hereditary prostate cancer: genes related, target therapy and prevention","volume":"22","author":"Vietri","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R6-20260905","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist Updat"},{"key":"R7-20260905","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41391-021-00394-5","article-title":"Advances in PSMA-targeted therapy for prostate cancer","volume":"25","author":"Wang","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R8-20260905","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.2967\/jnumed.120.243295","article-title":"Radionuclide therapy in prostate cancer: from standalone to combination PSMA theranostics","volume":"62","author":"Sandhu","year":"2021","journal-title":"J Nucl Med"},{"key":"R9-20260905","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R10-20260905","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R11-20260905","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/ph15101292","article-title":"177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"R12-20260905","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/pharmaceutics13010049","article-title":"Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications","volume":"13","author":"Nelson","year":"2020","journal-title":"Pharmaceutics"},{"key":"R13-20260905","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/ph15010013","article-title":"Expanding theranostic radiopharmaceuticals for tumor diagnosis and therapy","volume":"15","author":"Barca","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"R14-20260905","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"R15-20260905","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"R16-20260905","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with 177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"R17-20260905","doi-asserted-by":"crossref","first-page":"e2433863","DOI":"10.1001\/jamanetworkopen.2024.33863","article-title":"Lu-177 PSMA versus comparator treatments and survival in metastatic castration-resistant prostate cancer","volume":"7","author":"Soon","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R18-20260905","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1002\/cncr.35438","article-title":"Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: analysis of the phase 3 VISION trial","volume":"130","author":"Morris","year":"2024","journal-title":"Cancer"},{"key":"R19-20260905","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2967\/jnumed.122.264104","article-title":"The prognostic value of posttreatment 68Ga-PSMA-11 PET\/CT and 18F-FDG PET\/CT in metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617 and NOX66 in a Phase I\/II Trial (LuPIN)","volume":"64","author":"Pathmanandavel","year":"2023","journal-title":"J Nucl Med"},{"key":"R20-20260905","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2967\/jnumed.119.236414","article-title":"Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer","volume":"61","author":"Violet","year":"2020","journal-title":"J Nucl Med"},{"key":"R21-20260905","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2967\/jnumed.123.265414","article-title":"177Lu]Lu-PSMA-radioligand therapy efficacy outcomes in taxane-na\u00efve versus taxane-treated patients with metastatic castration-resistant prostate cancer: a systematic review and metaanalysis","volume":"64","author":"Satapathy","year":"2023","journal-title":"J Nucl Med"},{"key":"R22-20260905","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"R23-20260905","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"R24-20260905","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential 177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"key":"R25-20260905","first-page":"1068","article-title":"177Lu-PSMA-617 consolidation therapy after docetaxel in patients with synchronous high-volume metastatic hormone-sensitive prostate cancer: a randomized, phase 2 trial","volume":"66","author":"Satapathy","year":"2025","journal-title":"J Nucl Med"},{"key":"R26-20260905","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.euo.2022.09.002","article-title":"Neoadjuvant 177Lu-PSMA-I&T radionuclide treatment in patients with high-risk prostate cancer before radical prostatectomy: a single-arm phase 1 trial","volume":"6","author":"Golan","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"R27-20260905","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12885-023-10851-0","article-title":"The use of lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I\/II study (ROADSTER)","volume":"23","author":"Mendez","year":"2023","journal-title":"BMC Cancer"},{"key":"R28-20260905","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1097\/RLU.0000000000005163","article-title":"Complete resolution of locally advanced prostate cancer after molecular endoradiotherapy with 177Lu-PSMA","volume":"49","author":"Beheshti","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R29-20260905","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1186\/s13063-021-05733-4","article-title":"Update to a randomized controlled trial of lutetium-177-PSMA in oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial","volume":"22","author":"Priv\u00e9","year":"2021","journal-title":"Trials"},{"key":"R30-20260905","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3348\/kjr.2023.0656","article-title":"Dosimetric analysis of a phase I study of PSMA-targeting radiopharmaceutical therapy with 177Lu]Ludotadipep in patients with metastatic castration-resistant prostate cancer","volume":"25","author":"Ha","year":"2024","journal-title":"Korean J Radiol"},{"key":"R31-20260905","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.2967\/jnumed.121.262543","article-title":"Safety of PSMA-targeted molecular radioligand therapy with 177Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC (NCT03042312)","volume":"62","author":"Calais","year":"2021","journal-title":"J Nucl Med"},{"key":"R32-20260905","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-related quality of life and pain outcomes with 177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol"},{"key":"R33-20260905","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.eururo.2023.12.004","article-title":"Safety analyses of the phase 3 VISION trial of 177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"85","author":"Chi","year":"2024","journal-title":"Eur Urol"},{"key":"R34-20260905","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.prro.2024.10.014","article-title":"Management of dry mouth toxicity following 177Lu-PSMA-617 radioligand therapy","volume":"15","author":"Pepin","year":"2025","journal-title":"Pract Radiat Oncol"},{"key":"R35-20260905","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1007\/s00259-020-04856-1","article-title":"Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients","volume":"47","author":"Paganelli","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R36-20260905","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2967\/jnumed.121.262552","article-title":"177Lu-PSMA-617 and idronoxil in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): patient outcomes and predictors of treatment response in a phase I\/II trial","volume":"63","author":"Pathmanandavel","year":"2022","journal-title":"J Nucl Med"},{"key":"R37-20260905","doi-asserted-by":"crossref","first-page":"101445","DOI":"10.1016\/j.tranon.2022.101445","article-title":"Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: current concepts in imaging and management","volume":"21","author":"Mahajan","year":"2022","journal-title":"Transl Oncol"},{"key":"R38-20260905","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","article-title":"Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Groener","year":"2021","journal-title":"EJNMMI Res"},{"key":"R39-20260905","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","article-title":"PSMA-PET- and MRI-based focal dose escalated radiation therapy of primary prostate cancer: planned safety analysis of a nonrandomized 2-armed phase 2 trial (ARO2020-01)","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R40-20260905","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ijrobp.2022.12.055","article-title":"PSMA-PET\/CT-guided intensification of radiation therapy for prostate cancer (PSMAgRT): findings of detection rate, effect on cancer management, and early toxicity from a phase 2 randomized controlled trial","volume":"116","author":"Petit","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R41-20260905","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2967\/jnumed.119.237602","article-title":"Impact of 68Ga-PSMA-11 PET\/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study","volume":"61","author":"Sonni","year":"2020","journal-title":"J Nucl Med"},{"key":"R42-20260905","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2967\/jnumed.123.267004","article-title":"Randomized trial of prostate-specific membrane antigen PET\/CT before definitive radiotherapy for unfavorable intermediate- and high-risk prostate cancer (PSMA-dRT trial)","volume":"65","author":"Nikitas","year":"2024","journal-title":"J Nucl Med"},{"key":"R43-20260905","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/pros.24104","article-title":"Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted \u03b2-emitting radionuclide therapies in metastatic castration-resistant prostate cancer","volume":"81","author":"Vlachostergios","year":"2021","journal-title":"Prostate"},{"key":"R44-20260905","doi-asserted-by":"crossref","first-page":"e233460","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"key":"R45-20260905","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given 177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"key":"R46-20260905","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.eururo.2024.08.021","article-title":"Association of declining prostate-specific antigen levels with clinical outcomes in patients with metastatic castration-resistant prostate cancer receiving 177Lu]Lu-PSMA-617 in the phase 3 VISION trial","volume":"86","author":"Armstrong","year":"2024","journal-title":"Eur Urol"},{"key":"R47-20260905","doi-asserted-by":"crossref","first-page":"e14014","DOI":"10.1111\/eci.14014","article-title":"Prognostic role of early prostate specific antigen changes after 177Lu]Lu-PSMA radioligand therapy of metastasized prostate cancer: a meta-analysis","volume":"53","author":"Giovanella","year":"2023","journal-title":"Eur J Clin Invest"},{"key":"R48-20260905","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.2967\/jnumed.122.265346","article-title":"The impact of PSMA PET-based eligibility criteria used in the prospective phase II TheraP trial in metastatic castration-resistant prostate cancer patients undergoing prostate-specific membrane antigen-targeted radioligand therapy","volume":"64","author":"Karimzadeh","year":"2023","journal-title":"J Nucl Med"},{"key":"R49-20260905","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/RLU.0000000000003307","article-title":"Visceral metastases as predictors of response and survival outcomes in patients of castration-resistant prostate cancer treated with 177Lu-labeled prostate-specific membrane antigen radioligand therapy: a systematic review and meta-analysis","volume":"45","author":"Satapathy","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R50-20260905","doi-asserted-by":"crossref","first-page":"9054","DOI":"10.3390\/ijms21239054","article-title":"Optimizing PSMA radioligand therapy for patients with metastatic castration-resistant prostate cancer. A systematic review and meta-analysis","volume":"21","author":"von Eyben","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R51-20260905","doi-asserted-by":"crossref","first-page":"e0307826","DOI":"10.1371\/journal.pone.0307826","article-title":"Prognostic value of baseline alkaline phosphatase of 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"19","author":"Zhang","year":"2024","journal-title":"PLoS One"},{"key":"R52-20260905","doi-asserted-by":"crossref","first-page":"e232544","DOI":"10.1148\/radiol.232544","article-title":"Pharmacokinetic comparison of selective prostatic arterial and intravenous PSMA PET\/CT radioligand infusions in primary prostatic adenocarcinoma","volume":"312","author":"Kohlbrenner","year":"2024","journal-title":"Radiology"},{"key":"R53-20260905","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.2967\/jnumed.121.261982","article-title":"Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant prostate cancer (RESIST-PC): efficacy results of the UCLA cohort","volume":"62","author":"Calais","year":"2021","journal-title":"J Nucl Med"},{"key":"R54-20260905","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2967\/jnumed.119.233411","article-title":"Radiation dosimetry in 177Lu-PSMA-617 therapy using a single posttreatment SPECT\/CT scan: a novel methodology to generate time- and tissue-specific dose factors","volume":"61","author":"Jackson","year":"2020","journal-title":"J Nucl Med"},{"key":"R55-20260905","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.eururo.2022.05.025","article-title":"Extensive 177Lu-PSMA radioligand therapy can lead to radiation nephropathy with a renal thrombotic microangiopathy-like picture","volume":"83","author":"Sch\u00e4fer","year":"2023","journal-title":"Eur Urol"},{"key":"R56-20260905","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.2967\/jnumed.120.258533","article-title":"Liver enzyme elevation after 177Lu-PSMA radioligand therapy for metastasized castration-resistant prostate cancer","volume":"62","author":"Treiber","year":"2021","journal-title":"J Nucl Med"},{"key":"R57-20260905","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1097\/RLU.0000000000004781","article-title":"Excellent response to full-dose 177Lu-PSMA-617 RLT in metastatic castration-resistant prostate cancer with transplant kidney: a step ahead","volume":"48","author":"Mahdi","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R58-20260905","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1097\/RLU.0000000000003912","article-title":"Excellent response to adapted low-dose 177Lu-PSMA-617 PSMA therapy in renal compromise patient","volume":"47","author":"Usmani","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R59-20260905","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.7150\/thno.93249","article-title":"Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with 177Lu]Lu-PSMA-617 for prostate cancer \u2013 from bench to bedside","volume":"14","author":"Arbuznikova","year":"2024","journal-title":"Theranostics"},{"key":"R60-20260905","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12885-023-10725-5","article-title":"Tolerability of concurrent external beam radiotherapy and 177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment na\u00efve patients, phase I study (PROQURE-I trial)","volume":"23","author":"van der Sar","year":"2023","journal-title":"BMC Cancer"},{"key":"R61-20260905","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bju.15988","article-title":"LUNAR: a randomized phase 2 study of 177 Lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol)","volume":"132","author":"Ma","year":"2023","journal-title":"BJU Int"},{"key":"R62-20260905","first-page":"374","article-title":"Efficacy and safety of 177Lu-PSMA-617 in combination with radical prostatectomy and bilateral orchiectomy in men with castrate-sensitive metastatic prostate cancer: a pilot study","volume":"21","author":"Amanollahi Soudmand","year":"2024","journal-title":"Urol J"},{"key":"R63-20260905","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.euo.2020.07.002","article-title":"Phase I\/II trial of the combination of 177Lutetium prostate specific membrane antigen 617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN)","volume":"4","author":"Crumbaker","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"R64-20260905","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/RLU.0000000000005390","article-title":"177Lu-PSMA with olaparib radiosensitization potentiates response and toxicity in extensive castration-resistant metastatic prostate cancer","volume":"49","author":"Kao","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R65-20260905","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clgc.2023.02.010","article-title":"Phase 1 study of safety and preliminary clinical activity of JNJ-63898081, a PSMA and CD3 bispecific antibody, for metastatic castration-resistant prostate cancer","volume":"21","author":"Lim","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"R66-20260905","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","article-title":"A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R67-20260905","doi-asserted-by":"crossref","first-page":"e006794","DOI":"10.1136\/jitc-2023-006794","article-title":"Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report","volume":"11","author":"Reed-Perino","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R68-20260905","doi-asserted-by":"crossref","first-page":"e005702","DOI":"10.1136\/jitc-2022-005702","article-title":"First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)","volume":"11","author":"Autio","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R69-20260905","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T-cells in metastatic castration resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"R70-20260905","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","article-title":"First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"46","author":"Zang","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R71-20260905","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.2967\/jnumed.120.242263","article-title":"177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer","volume":"61","author":"Zang","year":"2020","journal-title":"J Nucl Med"},{"key":"R72-20260905","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00259-023-06470-3","article-title":"A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of 177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer","volume":"51","author":"Zang","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R73-20260905","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2967\/jnumed.124.267452","article-title":"Dosimetry of 177Lu]Lu-PSMA-targeted radiopharmaceutical therapies in patients with prostate cancer: a comparative systematic review and metaanalysis","volume":"65","author":"Ells","year":"2024","journal-title":"J Nucl Med"},{"key":"R74-20260905","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2967\/jnumed.122.265259","article-title":"Safety and efficacy of 177Lu]-PSMA-I&T radioligand therapy in octogenarians with metastatic castration-resistant prostate cancer: report on 80 patients over the age of 80 years","volume":"64","author":"Tauber","year":"2023","journal-title":"J Nucl Med"},{"key":"R75-20260905","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/RLU.0000000000004577","article-title":"Peritoneal metastases from prostate carcinoma treated with 177Lu-PSMA-I&T","volume":"48","author":"van Golen","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R76-20260905","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000531246","article-title":"Efficacy and safety of actinium-225 prostate-specific membrane antigen radioligand therapy in metastatic prostate cancer: a systematic review and metanalysis","volume":"32","author":"Parida","year":"2023","journal-title":"Med Princ Pract"},{"key":"R77-20260905","doi-asserted-by":"crossref","first-page":"840","DOI":"10.2967\/jnumed.121.262017","article-title":"Effects of 225Ac-labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: a meta-analysis","volume":"63","author":"Lee","year":"2022","journal-title":"J Nucl Med"},{"key":"R78-20260905","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41391-021-00349-w","article-title":"Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis","volume":"24","author":"Satapathy","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R79-20260905","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.7150\/thno.48107","article-title":"Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients","volume":"10","author":"Yadav","year":"2020","journal-title":"Theranostics"},{"key":"R80-20260905","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/RLU.0000000000005222","article-title":"Favorable response of 225 Ac-PSMA in the treatment of castration-resistant prostate cancer with high bone metastasis burden","volume":"49","author":"Wang","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R81-20260905","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1097\/RLU.0000000000004149","article-title":"Delayed nephrotoxicity after 225Ac-PSMA-617 radioligand therapy","volume":"47","author":"Satapathy","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R82-20260905","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.23.00573","article-title":"Prostate-specific membrane antigen-targeting alpha emitter via antibody delivery for metastatic castration-resistant prostate cancer: a phase I dose-escalation study of 225Ac-J591","volume":"42","author":"Tagawa","year":"2024","journal-title":"J Clin Oncol"},{"key":"R83-20260905","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12885-024-11900-y","article-title":"Evaluation of the tolerability and safety of 225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study","volume":"24","author":"Ling","year":"2024","journal-title":"BMC Cancer"},{"key":"R84-20260905","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(25)00332-8","article-title":"First-in-human results of terbium-161 161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1\/2 study","volume":"26","author":"Buteau","year":"2025","journal-title":"Lancet Oncol"},{"key":"R85-20260905","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.euo.2024.04.003","article-title":"Progression-directed therapy in oligoprogressive castration-resistant prostate cancer: final results from the prospective, single-arm, phase 2 MEDCARE trial","volume":"7","author":"Rans","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"R86-20260905","doi-asserted-by":"crossref","first-page":"e185408","DOI":"10.1172\/JCI185408","article-title":"68Ga-MY6349 PET\/CT imaging to assess Trop2 expression in multiple types of cancer","volume":"135","author":"Chen","year":"2024","journal-title":"J Clin Invest"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aja2025103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T09:00:50Z","timestamp":1788598850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja2025103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":86,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aja2025103","relation":{},"ISSN":["1008-682X","1745-7262"],"issn-type":[{"value":"1008-682X","type":"print"},{"value":"1745-7262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"2025-06-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}